Compare JFBR & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JFBR | ONCO |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Israel | United States |
| Employees | 11 | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4M | 1.4M |
| IPO Year | N/A | 2021 |
| Metric | JFBR | ONCO |
|---|---|---|
| Price | $3.01 | $0.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 445.0K | ★ 4.0M |
| Earning Date | 03-31-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.29 | $0.09 |
| 52 Week High | $7.87 | $7.65 |
| Indicator | JFBR | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 53.17 |
| Support Level | $0.47 | $0.49 |
| Resistance Level | $3.70 | $1.87 |
| Average True Range (ATR) | 0.34 | 0.10 |
| MACD | -0.26 | 0.03 |
| Stochastic Oscillator | 35.58 | 63.67 |
Jeffs Brands Ltd is an e-commerce CPG company, operating on Amazon. The company serves as the holding company of other e-commerce companies, Smart Repair Pro, Purex, and Top Rank, that operate online stores for the sale of various consumer products on Amazon online marketplace, utilizing the FBA model. The company has five wholly-owned subsidiaries: Smart Repair Pro, Purex, Top Rank, Fort and Jeffs' Brands Holdings. The company also utilizes internal methodologies to analyze sales data and patterns on Amazon to identify existing stores, niches, and products that have the potential for development and growth, and for maximizing sales of existing proprietary products.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.